Title here

Text here

Cancer Research Institute, Inc.

AKA CRI

New York, NY

GuideStar Quick View Everything you need to know...


Legitimacy Information

  • This organization is registered with the IRS.
  • This organization is required to file an IRS Form 990 or 990-EZ.

Institutional funders should note that an organization’s inclusion on GuideStar.org does not satisfy IRS Rev. Proc. 2011-33 for identifying supporting organizations.

Learn more about GuideStar Charity Check, the only pre-grant due diligence tool that is 100% compliant with IRS Rev. Proc 2011-33.


Forms 990 from IRS Additional Information IRS Form 990 is an annual document used by approximately one-third of all public charities to report information about their finances and operations to the federal government. GuideStar uses data from Form 990 to populate its database with financial information about nonprofit organizations. Posting Form 990 images on the GuideStar Web site is an ongoing process.

Forms 990 for 2013, 2012, 2011, 2010, 2009 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart

A multi-year analysis of key balance sheet, income statement, profitability and liquidity measures is available for this organization. Financial SCAN includes a detailed financial health analysis and peer comparison and benchmarking tool. Learn More

Financial SCAN

Financial SCAN

Key Financial SCAN Features

  • Financial Health Dashboard: Highlights key financial trends and ratios for a selected nonprofit organization over a period of up to five years.
  • Peer Comparison Dashboard: Compares the organization's financials with up to five peer nonprofits that you select.
  • Graphical Analysis: Provides multi-year graphs and an interpretive guide in a format ready to present to your clients.
  • Printable PDF Report: Provides a complete analysis of the organization for your records. The full report tells you what to look for and why it matters.
  • Advanced Search: Allows you to search by EIN (Employer Identification Number), organization name, city, state, revenue, expenses, and assets.

Annual Revenue & Expenses Additional Information Financial information on GuideStar is either digitized from Form 990 images we receive from the IRS or submitted by the nonprofits themselves through the GuideStar Exchange (990 filers cannot override Form 990 financial data). If your organization does not file a Form 990, 990-EZ, or 990-PF and you would like to have your financial data displayed in this section, join the GuideStar Exchange today!

Fiscal Year Starting: July 1, 2012
Fiscal Year Ending: June 30, 2013
Revenue
Total Revenue $20,031,481
Expenses
Total Expenses $18,585,045

Is this information up-to-date?
Claim your report and update your GuideStar Exchange profile today!

Financial data from Forms 990 for Year 2012, 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart

A multi-year analysis of key balance sheet, income statement, profitability and liquidity measures is available for this organization. Financial SCAN includes a detailed financial health analysis and peer comparison and benchmarking tool. Learn More

Financial SCAN

Financial SCAN

Key Financial SCAN Features

  • Financial Health Dashboard: Highlights key financial trends and ratios for a selected nonprofit organization over a period of up to five years.
  • Peer Comparison Dashboard: Compares the organization's financials with up to five peer nonprofits that you select.
  • Graphical Analysis: Provides multi-year graphs and an interpretive guide in a format ready to present to your clients.
  • Printable PDF Report: Provides a complete analysis of the organization for your records. The full report tells you what to look for and why it matters.
  • Advanced Search: Allows you to search by EIN (Employer Identification Number), organization name, city, state, revenue, expenses, and assets.



GuideStar Exchange Member

This organization is a Gold-level GuideStar Exchange participant, demonstrating its commitment to transparency.

Is this your organization's report?
Update your organization's information today!


Basic Organization Information

Cancer Research Institute, Inc.

Also Known As:
CRI
Physical Address:
New York, NY 10006 
EIN:
13-1837442
Web URL:
www.cancerresearch.org 
NTEE Category:
H Medical Research 
H30 Cancer Research 
H Medical Research 
H90 Medical Specialty Research 
H Medical Research 
H12 Fund Raising and/or Fund Distribution 
Ruling Year:
1953 

Sign in or create an account to see this organization's full address, contact information, and more!


Mission Statement

The Cancer Research Institute (CRI) is harnessing the power of the immune system to bring new and more effective approaches to cancer treatment, control, and prevention to cancer patients sooner. To accomplish this, CRI funds and coordinates an international network of laboratory and clinical research scientists working within the fields of immunology and tumor immunology. Through integration of basic and clinical research initiatives, CRI is accelerating the discovery, testing, and optimization of next-generation cancer immunotherapies such as cancer vaccines and antibodies. The Cancer Research Institute identifies top scientific talent through the guidance of the CRI Scientific Advisory Council (SAC), an international roster of leaders in the field of immunology who support CRI's efforts to foster creative, scientifically rigorous research. The SAC counts among its members three Nobel Laureates, 31 members of the National Academy of Sciences, and 24 members of the Academy of Cancer Immunology.

A multi-year analysis of key balance sheet, income statement, profitability and liquidity measures is available for this organization. Financial SCAN includes a detailed financial health analysis and peer comparison and benchmarking tool. Learn More

Financial SCAN

Financial SCAN

Key Financial SCAN Features

  • Financial Health Dashboard: Highlights key financial trends and ratios for a selected nonprofit organization over a period of up to five years.
  • Peer Comparison Dashboard: Compares the organization's financials with up to five peer nonprofits that you select.
  • Graphical Analysis: Provides multi-year graphs and an interpretive guide in a format ready to present to your clients.
  • Printable PDF Report: Provides a complete analysis of the organization for your records. The full report tells you what to look for and why it matters.
  • Advanced Search: Allows you to search by EIN (Employer Identification Number), organization name, city, state, revenue, expenses, and assets.

Financial Data

Sign in or create an account to view Revenue and Expense data for the most recent fiscal year.


Revenue and Expenses

Sign in or create an account to view this information for the most recent fiscal year.

Revenue and Expense data from Forms 990 for 2012, 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart


Balance Sheet

Balance Sheet data from Forms 990 for Year 2012, 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart

A multi-year analysis of key balance sheet, income statement, profitability and liquidity measures is available for this organization. Financial SCAN includes a detailed financial health analysis and peer comparison and benchmarking tool. Learn More

Financial SCAN

Financial SCAN

Key Financial SCAN Features

  • Financial Health Dashboard: Highlights key financial trends and ratios for a selected nonprofit organization over a period of up to five years.
  • Peer Comparison Dashboard: Compares the organization's financials with up to five peer nonprofits that you select.
  • Graphical Analysis: Provides multi-year graphs and an interpretive guide in a format ready to present to your clients.
  • Printable PDF Report: Provides a complete analysis of the organization for your records. The full report tells you what to look for and why it matters.
  • Advanced Search: Allows you to search by EIN (Employer Identification Number), organization name, city, state, revenue, expenses, and assets.


Forms 990 Provided by the Nonprofit

Sign in or create an account to view Form(s) 990 for 2011, 2010, 2009.


Financial Statements

Financial Statements for 2011, 2011, 2010 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart


Annual Reports

Sign in or create an account to view this information.



Leadership (GuideStar ExchangeThe GuideStar Exchange allows nonprofits to regularly update key information directly to GuideStar. It provides richer and broader information about their programs, impact, finances, people and more. February, 2014)

Jill O'Donnell-Tormey, Ph.D., Ph.D.

Term:

Since Feb 1993

Profile:

Dr. Jill O'Donnell-Tormey is a trained cell biologist and immunologist who has been the executive director of the Cancer Research Institute since 1993. During that time, she has been instrumental in increasing the Institute's annual budget twofold. She oversaw the establishment of the Institute's cancer-specific programs, created the International Cancer Immunotherapy Symposia Series, and played a pivotal role in developing the Institute's Clinical Investigation Program, which includes the Cancer Vaccine Collaborative and the Cancer Antigen Discovery Collaborative. She works closely with the Institute's Scientific Advisory Council Director, Lloyd J. Old, M.D., and the Board of Trustees to chart the Institute's strategic course. Prior to her role as Executive Director, Dr. O'Donnell-Tormey served as the Institute's Director of Scientific Affairs from 1987-1993. In that capacity, she greatly increased the Institute's public information program, resulting in the publication of the informative "CRI HelpBook: What To Do If Cancer Strikes" and the highly regarded primer on the field of cancer immunology entitled "Cancer and the Immune System: The Vital Connection," which has recently been updated and is available on the Institute's web site. Dr. O'Donnell-Tormey holds a Bachelor of Science Degree in Chemistry from Farleigh Dickenson University and a Doctor of Philosophy in Cell Biology from The State University of New York's Downstate Medical Center.

Leadership Statement:

Cancer is a disease that affects everyone. While there have been strides in chemotherapy, radiation therapy, and surgical treatments of the disease, cancer continues to claim the lives of millions of people each year. There is a clear and urgent need to develop new approaches to cancer treatment and prevention. The Cancer Research Institute is dedicated to finding novel ways to harness the power of our own immune systems to conquer cancer. Our work has already made an impact in the lives of people combating cancer. Our Web site (http://www.cancerresearch.org(http://www.cancerresearch.org) ) contains inspirational stories of cancer patients who have participated in early clinical studies of new immunotherapies and who are benefiting from the tremendous strides we are making. You will also read about some of our most talented scientists, whose discoveries are shaping the future of cancer treatment. I encourage you to take time to browse the site and find out what makes us such a unique and vital force in the search for new and better ways to treat, control, and prevent cancer. Perhaps you may be interested in reading our educational publications, learning about exciting scientific breakthroughs funded by CRI, discovering the rich and vibrant history of the organization(/AboutUs.aspx?id=206) , or finding out how to become involved in one of our special events(/Events.aspx?id=38) . You may even decide that you, too, would like to become part of this important effort by making a donation to support our work. Thank you for your interest in the Cancer Research Institute. We hope that you will join us as we work together to usher in a new era of cancer therapy.



Officers for Fiscal Year (IRS Form 990)

Report Added To Cart Officers for 2012, 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now


Highest Paid Employees & Their Compensation (IRS Form 990)

Highest Paid Employee Data for 2012, 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart


Program: Student Training and Research in Tumor Immunology (STaRT)

Budget:
$240,000
Category:
Cancer Research
Population Served:
None
None
None

Program Description:

The Student Training and Research in Tumor Immunology (STaRT) program seeks to attract bright young minds to rewarding careers as cancer immunologists. STaRT grants provide up to $60,000 of support over two years for graduate students conducting thesis research in the area of tumor immunology. Students selected for the program can receive early exposure during their formative studies to exciting, emerging areas of investigation within the field of cancer immunology. In addition, student participation in annual Cancer Research Institute symposia introduces them into the tight-knit community of leading tumor immunologists.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Predoctoral Emphasis Pathways in Tumor Immunology

Budget:
--
Category:
Cancer Research
Population Served:
None
None
None

Program Description:

Initiated in 1998, the Predoctoral Emphasis Pathways program provides funding to universities to establish training curricula designed to capture the interest of talented researchers at the earliest stage. Grants support doctoral students planning to pursue a career in cancer immunology. Through meetings, journal clubs, lectures, and coursework, students gain exposure to emerging and promising areas in the field of tumor immunology. CRI provided ongoing grant support to nine institutions in the U.S., Australia, and Russia.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Irvington Postdoctoral Fellowship Program

Budget:
$3,600,000
Category:
Cancer Research
Population Served:
None
None
None

Program Description:

The CRI Irvington Postdoctoral Fellowship Program, established in 1971, is CRI’s longest-standing continuous program. Fellowships provide support to fund and train young immunologists and cancer immunologists at top universities and research centers around the world. Fellows receive up to $164,500 over three years to cover the cost of stipend or salary, insurance, and other research-related expenses, such as travel to conferences and meetings. Fellows work and continue their training under the guidance of a world-leading immunologist, who mentors the fellow and prepares him or her for a productive and successful career in cancer immunology.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Investigator Award Program

Budget:
--
Category:
Cancer Research
Population Served:
None
None
None

Program Description:

The Investigator Award Program, established in 1986 to complement our fellowship program, supports accomplished assistant professors who are undertaking their first independent investigations in basic and tumor immunology. By awarding these researchers $50,000 per year for four years, the program provides flexibility and a degree of stability during this very challenging period in an academic scientist’s career. A seven-person panel selects recipients based on the applicant’s entire body of research, rather than on a single project. In fiscal 2013, CRI provided ongoing grant support to 14 investigators in the U.S., Japan, and the United Kingdom.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Clinic and Laboratory Integration Program (CLIP)

Budget:
$1,600,000
Category:
Cancer Research
Population Served:
None
None
None

Program Description:

The Clinic and Laboratory Integration Program (CLIP) supports qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The program funds basic, pre-clinical, and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CLIP grants provide up to $200,000 over four years.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Clinical Accelerator

Budget:
$8,700,000
Category:
Cancer Research
Population Served:
None
None
None

Program Description:

The Clinical Accelerator is an actively managed venture philanthropy program designed to speed the development of cancer immunotherapies. The strategy facilitates research collaboration across leading biopharma companies and among 50 of the world’s top cancer researchers. The program aims to identify and kick-start development of next generation combination treatments using the most promising drugs from disparate companies. Each philanthropic investment brings a new cancer treatment to patients, empowers academic researchers to work more closely with industry, and creates the potential for significant future returns on investment back to CRI to make the venture fund self-sustaining. Launched in mid-2012, the program has created partnerships with or is finalizing terms with more than 15 of the field’s top companies. Four core resources empower the Clinical Accelerator: *Coordinated Network of Researchers The Cancer Vaccine Collaborative (CVC) Trials Network, managed jointly by the Cancer Research Institute and Ludwig Cancer Research, is a coordinated global network of nearly 50 clinical investigators with special expertise in immunology. Investigators conduct parallel early-stage clinical trials to identify the optimal composition of successful cancer immunotherapy combinations, and guide the selection of therapeutic agents and trials. *Nonprofit Venture Fund CRI’s venture fund is designed to speed clinical development of promising cancer immunotherapies. It provides nonprofit investment capital to support the costs of priority clinical studies that the CVC view to be potentially transformational for patients and for the field. Successful drugs result in milestone payments back to the nonprofit fund, enabling it to become self-sustaining over time. *Clinical Trials Management Our partner, Ludwig Cancer Research, sponsors and manages trials conducted with the CVC Trials Network, enabling the program to independently manage multi-site trials. Their capabilities support all aspects of study design and set-up, regulatory sponsorship, medical monitoring, drug safety, data capture and processing, and clinical study reports and analyses, for our CVC-designed trials. *Portfolio of BioPharma Partnerships Through agreements with biotech and pharmaceutical leaders in the cancer immunotherapy space, the CVC Trials Network gains access to top immunotherapies. By providing a menu of promising drugs and permitting CVC investigators to combine drugs owned by disparate companies, these partnerships allow clinical data on new combinations to be generated in advance of and independent of any commercial transactions between the owners, circumventing an often laborious negotiation process and thus accelerating clinical research of immunotherapy combinations.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Grants and Patient Support

Budget:
$405,000
Category:
People/Families of People with Cancer
Population Served:
None
None
None

Program Description:

These grants support research projects and public education and awareness initiatives for which, in most cases, donors have specifically raised funds.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Annual International Cancer Immunotherapy Symposium

Budget:
--
Category:
Cancer Research
Population Served:
None
None
None

Program Description:

Established in 1993, this series of annual meetings focuses on progress in cancer immunology with special focus on cancer vaccine and antibody research. In fiscal year 2013, CRI hosted the 20th annual meeting in this series, titled, “From Milestones to Medicines: Translating Tumor Immunology Research into Immunotherapies.” More than 360 students, postdoctoral fellows, and investigators from more than 70 academic institutions and biopharmaceutical companies attended the meeting, which was dedicated to the late Dr. Lloyd J. Old, under whose leadership the series was founded. The meeting also included a poster session with presentations by nearly 130 scientists, six of which were invited to deliver a lecture during the general session.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Annual Scientific Colloquium of the CRI Cancer Immunotherapy Consortium

Budget:
--
Category:
Cancer Research
Population Served:
None
None
None

Program Description:

CRI organizes annual meetings of the Cancer Immunotherapy Consortium, providing a forum for industry and academic leaders in cancer immunotherapy research and development. In fiscal year 2013, CRI hosted the 14th annual Scientific Colloquium titled, “Entering the Era of Combination Therapies: Practical Implementation.” The meeting brought together leaders from the regulatory, scientific, and business communities to present new methodological tools, leading-edge scientific data from ongoing combination studies, and innovative models of academic-industry collaboration that are helping to overcome challenges to optimizing combination cancer therapies for the benefit of patients.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:

Program: Annual Honorary Awards

Budget:
--
Category:
None
Population Served:
None
None
None

Program Description:

In addition to providing financial support to researchers and investigators, CRI also honors scientists and community leaders with achievement awards. These awards are presented at our annual dinner. *William B. Coley Award for Distinguished Research in Basic and Tumor Immunology CRI grants the Coley Award annually to one or more scientists whose discoveries in the fields of immunology or tumor immunology contribute to the advancement of immune system-based therapies for cancer. CRI established the award in 1975 in honor of Dr. William B. Coley, the acknowledged “Father of Cancer Immunotherapy,” whose daughter, Helen Coley Nauts (1907-2001), founded the Cancer Research Institute. *Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research CRI’s Grace Award annually recognizes the contributions of dedicated laypersons whose leadership has had a significant impact on cancer research. The award is named in memory of Oliver R. Grace (1909-1992), the founding chairman of CRI, whose vision, leadership, wisdom, and generosity guided and continues to benefit the Institute. *Frederick W. Alt Award for New Discoveries in Immunology The Alt Award honors a former postdoctoral fellow in recognition of outstanding success in academia or industry for research that may have a potentially major impact on immunology. The award is named after CRI Scientific Advisory Council member Frederick W. Alt, Ph.D., who not only has made many seminal contributions to the field of immunology, but also has mentored generations of young scientists. *AACR-CRI Lloyd J. Old Award in Cancer Immunology Named in honor of CRI’s founding scientific and medical director, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, funded in partnership with the American Association for Cancer Research, recognizes an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field. *Helen Coley Nauts Service Award This award honors individuals who have made significant contributions of time, energy, and service to CRI. The award is named in memory of CRI’s founder, Helen Coley Nauts, who dedicated her life to advancing immune system-based therapies for cancer.

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:



Contractor data is available for this organization!

Independent Contractor information for 2012, 2009, 2008 is available for this organization with a subscription to GuideStar Premium Pro.

GuideStar Premium Pro also includes:

  • Comprehensive financial data, including functional expense detail, for every digitized fiscal year in GuideStar's database
  • Ability to download up to 55 fields of data for up to 1,000 organizations at a time and up to five years’ worth of Income Statement and Balance Sheet data for individual organizations
  • Comprehensive advanced search capabilities, including criteria for functional expenses, investible assets, investment income and audit & 990T filing requirements
  • Ability to save organizations and searches for quick reference
  • People search with salary range data
  • Access to all available Forms 990

More information

Upgrade Now!

Impact Summary from the Nonprofit Additional Information A Charting Impact Report consists of an organization’s responses to the five questions. Helping validate this self-reported data are three reviews. Once an organization has used the online interface to complete its report, its responses will produce a document with a unique URL that will be shared on this website, on your GuideStar profile, on the reports of charities participating in BBB Wise Giving Alliance evaluations, and – in the future – with other websites and information sources about nonprofits. We encourage organizations to use this URL to share their report on their own website and through their own media channels. Participants will receive guidance about promoting their Charting Impact Report, along with other benefits, once they publish their report.

The Cancer Research Institute's support of the fields of immunology and tumor immunology over the past 60+ years has been essential to providing the basic knowledge needed to advance new ideas for immune-based cancer therapies, like cancer vaccines and antibody therapies. Recent FDA approvals of immunotherapies based on the research of CRI scientists include Gardasil (2006), a preventive vaccine for cervical cancer; Provenge (2010), a therapeutic vaccine for prostate cancer; and Yervoy (2011), an antibody to treat advanced melanoma. Our researchers have made key contributions to our understanding of the immune system, its relationship to cancer, how cancer cancer defends itself against the immune system, and how to stimulate and maintain effective anti-cancer immune responses that destroy or control cancer indefinitely, with minimal harm to a patient's quality of life. In 2011, three Cancer Research Institute-supported immunologists won the Nobel Prize (Beutler, Hoffmann, Steinman) for their contributions to understanding immune system activation. Many more CRI-funded scientists have received top honors and now hold positions of authority within major cancer treatment centers.   Through our Cancer Vaccine Collaborative, a joint program with Ludwig Cancer Research, the Cancer Research Institute is spearheading a coordinated, global, academic research effort to learn how best to vaccinate against cancer. In only ten years since its founding, the CVC has conducted nearly 50 clinical trials of different therapeutic vaccine combinations and has produced one of the largest bodies of knowledge on the impact of cancer antigen-specific active immunotherapy.   With these efforts, the Cancer Research Institute is working to bring a new class of cancer treatments--cancer immunotherapy--to patients sooner.
For more in-depth information about this organization's impact, view their Charting Impact Report.

Organization Data Available

Adobe PDF Format A GuideStar Premium Report in PDF format is available for this organization

Price for this Report: $125.00

This Premium Report includes:

  • Financial Data for
  • Financial Charts for
  • Forms 990 for
  • Forms 990T for
  • Audited Financial Statement for
  • Annual Reports for
  • Letter of Determination
  • Form 1023 / 1024
  • Board Members
  • Officer, Director and/or Highest Paid Employee data for


Learn more about GuideStar Premium